by TractManager | Mar 11, 2021 | Health Technology Assessment
Focus of the Report: Oral anticoagulation (OAC) is standard care to reduce the risk of stroke in patients with atrial fibrillation (AF) and risk factors for stroke. Limitations of OAC therapy have spurred the development of nonpharmaceutical approaches to prevent...
by TractManager | Mar 10, 2021 | News
The United States Preventive Services Task Force (USPSTF) has issued an updated recommendation statement on screening for lung cancer. The USPSTF has modified the age range and smoking history recommended for screening. The USPSTF now recommends annual screening for...
by TractManager | Mar 8, 2021 | Emerging Technology Report
Evrysdi (risdiplam; formerly RG7916) is an oral small molecule splicing modifier of the survival motor neuron 2 (SMN2) gene indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older. If you have a Hayes login, click here to...
by TractManager | Mar 3, 2021 | News
These Food and Drug Administration (FDA) approvals were recently announced:Nulibry (fosdenopterin)On February 26, 2021, the FDA approved a new drug application for Nulibry (fosdenopterin; Origin Biosciences Inc.) to reduce the risk of of mortality in patients with...
by TractManager | Mar 2, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on venous sinus stenting (VSS) for treatment of idiopathic intracranial hypertension (IIH) that has failed to respond to available drug and conservative treatments.Technology Description: VSS is an endovascular procedure...
Recent Comments